1. Volume 73, Issue 6, Pages 847-855 (June 2018)
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG- AFU15 Studies 
Gwenaelle Gravis, Jean-Marie Boher, Yu-Hui Chen, Glenn Liu, Karim Fizazi, Michael A. Carducci, Stephane Oudard, Florence Joly, David M. Jarrard, Michel Soulie, Mario J. Eisenberger, Muriel Habibian, Robert Dreicer, Jorge A. Garcia, Maha H.M. Hussain, Manish Kohli, Nicholas J. Vogelzang, Joel Picus, Robert DiPaola, Christopher Sweeney 
European Urology 
Volume 73, Issue 6, Pages (June 2018)
DOI: /j.eururo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Disposition of patients in the CHAARTED and GETUG-AFU15 studies.
ADT=androgen deprivation therapy; D=docetaxel; HV=high volume; LV=low volume.
a Including nonevaluable patients.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Overall survival in (A) patients with high-volume disease and metastases at initial diagnosis of prostate cancer, (B) patients with high-volume disease and prior local treatment (no metastases at initial diagnosis of prostate cancer), (C) patients with low-volume disease and metastases at initial diagnosis of prostate cancer, and (D) patients with low-volume disease and prior local treatment (no metastases at initial diagnosis of prostate cancer).
ADT=androgen deprivation therapy; D=docetaxel.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 European Association of Urology Terms and Conditions